Zoetis Inc. (ETR:ZOE)
Germany · Delayed Price · Currency is EUR | Market Cap | 55.18B |
| Revenue (ttm) | 7.99B |
| Net Income (ttm) | 2.22B |
| Shares Out | n/a |
| EPS (ttm) | 4.95 |
| PE Ratio | 24.81 |
| Forward PE | 22.56 |
| Dividend | 1.75 (1.43%) |
| Ex-Dividend Date | Jul 18, 2025 |
| Volume | 1 |
| Average Volume | 121 |
| Open | 122.56 |
| Previous Close | 124.46 |
| Day's Range | 122.56 - 122.56 |
| 52-Week Range | 122.56 - 179.58 |
| Beta | 0.89 |
| RSI | 29.49 |
| Earnings Date | Nov 3, 2025 |
About Zoetis
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health products in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other ph... [Read more]
Full Company ProfileFinancial Performance
In 2024, Zoetis's revenue was $9.26 billion, an increase of 8.33% compared to the previous year's $8.54 billion. Earnings were $2.49 billion, an increase of 6.06%.
Financial numbers in USD Financial StatementsNews
Zoetis (ZTS) Stock Declines While Market Improves: Some Information for Investors
In the closing of the recent trading day, Zoetis (ZTS) stood at $146.25, denoting a -1.32% move from the preceding trading day.
January 2028 Options Now Available For Zoetis (ZTS)
Investors in Zoetis Inc (Symbol: ZTS) saw new options begin trading today, for the January 2028 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the tim...
Zoetis Gains CVMP Backing for Portela, Eyes EU Approval in Cat OA Pain
ZTS secures CVMP's positive opinion recommending the approval of Portela, a long-acting OA pain therapy for cats, with final decision expected in late 2025.
Zoetis (ZTS) Awaits EU Approval for Innovative Cat Osteoarthritis Therapy
Zoetis (ZTS) Awaits EU Approval for Innovative Cat Osteoarthritis Therapy
Zoetis Receives Positive Opinion from CVMP for Portela® (relfovetmab) to Alleviate Pain Associated with Osteoarthritis in Cats
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--If approved, Zoetis' Portela will be the first long-acting anti-NGF mAb therapy for cats and is designed to provide 3 months of OA pain relief...
Argus Research Reiterates Buy Rating for ZTS with Price Target Unchanged | ZTS Stock News
Argus Research Reiterates Buy Rating for ZTS with Price Target Unchanged | ZTS Stock News
Zoetis Inc. (ZTS) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Top 50 High-Quality Dividend Stocks For September 2025
I track a universe of 50 high-quality dividend growth stocks to identify attractive investment opportunities based on valuation and future return potential. My custom valuation model highlights 23 sto...
ZOE Released White Paper on European VPP and Energy Storage Development
SHANGHAI, Sept. 3, 2025 /PRNewswire/ -- ZOE Energy Storage, a leading BloombergNEF tier 1 provider of integrated ESS solutions, released the European Virtual Power Plant (VPP) and Energy Storage Devel...
Phibro Animal Health: Zoetis Growth, Valuation Still Attractive
Zoetis: A Solid Dividend Growth Investment For The Long Haul
Zoetis leads in animal health with strong growth, innovation, and safe, fast-growing dividends—now trading near fair value. Learn why ZTS stock is a buy.
Phibro targets 10–14% sales growth for 2026 as Zoetis integration and Phibro Forward drive momentum
Zoetis to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) today announced that a representative from the company will participate in the Morgan Stanley 23rd Annual Global Health...
Zoetis: Why I Decided To Invest In The Stock
Zoetis Announces Pricing of $1.85 Billion of Senior Notes
Zoetis Inc. (NYSE:ZTS) today announced that it has agreed to sell $1.850 billion of senior notes, consisting of $850.0 million aggregate principal amount of 4.150% senior notes due 2028 and $1.0 billi...
Zoetis Announces Pricing of $1.85 Billion of Senior Notes
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) today announced that it has agreed to sell $1.850 billion of senior notes, consisting of $850.0 million aggregate princ...
If You'd Invested $1,000 in Zoetis (ZTS) Stock 10 Years Ago, Here's How Much You'd Have Today
The short-term picture has been less rosy than the longer-term one.
.jpeg?width=1200&auto=webp&crop=3%3A2)
ZOE's Dr Federica Amati: 'Taking the Tube is the unhealthiest part of my day — the pollutants are awful'
Waking up with water, a sauna at lunchtime and putting together a healthy meal are the doctor’s wellbeing secrets
Top 50 High-Quality Dividend Stocks For August 2025
My investable universe of 50 high-quality dividend growth stocks aims to identify attractive opportunities based on valuation and future return potential. Currently, 20 stocks offer an estimated futur...
Zoetis CEO: It's unclear if animal health will be a part of pharmaceutical tariffs
Kristin Peck, Zoetis CEO, joins 'Closing Bell: Overtime' to discuss Q2 earnings, tariff impact on business and domestic production.
Zoetis CEO: It's unclear if animal health will be a part of pharmaceutical tariffs
Kristin Peck, Zoetis CEO, joins 'Closing Bell: Overtime' to discuss Q2 earnings, tariff impact on business and domestic production.
Zoetis raises 2025 organic operational revenue growth guidance to up to 8% while advancing key franchises
Zoetis Inc. 2025 Q2 - Results - Earnings Call Presentation
Zoetis Inc. (ZTS) Q2 2025 Earnings Call Transcript
Zoetis Lifts Outlook As Companion Animal Portfolio Offsets Librela Decline
Animal health firm Zoetis Inc. ZTS on Tuesday reported a second-quarter 2025 adjusted earnings per share of $1.76, up from $1.56 a year ago, beating the consensus of $1.61.